Adam Boxer, MD, PhD
Adam Boxer, MD, PhD, and Howie Rosen, MD, of the Memory and Aging Center (MAC), have won a $6.25 million grant to study Frontotemporal Lobar Degeneration (FTLD) through the Rare Diseases Clinical Research Network (RDCRN), which is led by National Institute’s of Health’s National Center for Advancing Translational Sciences (NCATS).
FTLD strikes people at younger ages than Alzheimer’s and is uniformly fatal, but is a better defined population to develop drugs that may ultimately be effective in both FTLD and Alzheimer’s.
The network will have 14 centers around North America, including the MAC. A number of companies are interested in using these sites to test new drugs they've developed based on the science that has come out of studying FTLD.